Inthera Bioscience is a Zurich-based biopharmaceutical company that develops targeted small-molecule therapies for solid tumors. It employs a proprietary technology platform to rationally design small-molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs focus on novel oral agents that block aberrant cell signaling in solid tumors and are currently in pre-clinical development. Founded in 2013 by Ulrich Kessler and Paramjit Arora, Inthera’s lead program targets HPV-associated cancers. The company will use the Series A proceeds to complete pre-clinical development of its lead program and to expand operations and the pipeline. As part of the financing, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures joined Inthera’s Board of Directors. Inthera Bioscience is a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors. The company employs a proprietary technology platform to rationally design inhibitors of protein-protein interactions. It has discovered potent disruptors of hypoxia-inducible signaling and targeted agents against HPV-associated cancer, with programs currently in preclinical development. Inthera aims to advance its lead program from in vivo proof-of-concept into the clinic and to expand its emerging pipeline. The company was founded in 2013 by Dr. Ulrich Kessler and Prof. Paramjit Arora. Inthera recently completed a $3.7 million (EUR 3.4 million) financing to support these near-term development plans.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

May 2017